Brown Brothers Harriman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.36M | Buy |
8,785
+2,947
| +50% | +$1.31M | 0.02% | 239 |
|
|
2026
Q1 | $2.61M | Buy |
5,838
+1,320
| +29% | +$616K | 0.01% | 273 |
|
|
2025
Q4 | $2.05M | Buy |
4,518
+1,399
| +45% | +$603K | 0.01% | 273 |
|
|
2025
Q3 | $1.22M | Buy |
3,119
+197
| +7% | +$82.3K | 0.01% | 317 |
|
|
2025
Q2 | $1.3M | Buy |
2,922
+92
| +3% | +$42.4K | 0.01% | 290 |
|
|
2025
Q1 | $1.37M | Sell |
2,830
-12
| -0.4% | -$5.59K | 0.01% | 259 |
|
|
2024
Q4 | $1.14M | Buy |
2,842
+364
| +15% | +$169K | 0.01% | 281 |
|
|
2024
Q3 | $1.15M | Sell |
2,478
-26
| -1% | -$12.5K | 0.01% | 274 |
|
|
2024
Q2 | $1.17M | Buy |
2,504
+104
| +4% | +$45.1K | 0.01% | 246 |
|
|
2024
Q1 | $1M | Sell |
2,400
-114
| -5% | -$48.2K | 0.01% | 264 |
|
|
2023
Q4 | $1.02M | Sell |
2,514
-189
| -7% | -$69.8K | 0.01% | 254 |
|
|
2023
Q3 | $940K | Buy |
2,703
+83
| +3% | +$29K | 0.01% | 258 |
|
|
2023
Q2 | $922K | Buy |
2,620
+92
| +4% | +$31K | 0.01% | 254 |
|
|
2023
Q1 | $796K | Buy |
2,528
+59
| +2% | +$17.7K | 0.01% | 276 |
|
|
2022
Q4 | $713K | Sell |
2,469
-10
| -0.4% | -$3.05K | 0.01% | 264 |
|
|
2022
Q3 | $718K | Buy |
2,479
+16
| +0.6% | +$4.6K | 0.01% | 261 |
|
|
2022
Q2 | $694K | Buy |
2,463
+44
| +2% | +$11.8K | 0.01% | 267 |
|
|
2022
Q1 | $631K | Buy |
2,419
+84
| +4% | +$19.9K | ﹤0.01% | 312 |
|
|
2021
Q4 | $513K | Sell |
2,335
-327
| -12% | -$63.6K | ﹤0.01% | 339 |
|
|
2021
Q3 | $483K | Sell |
2,662
-51
| -2% | -$9.96K | ﹤0.01% | 331 |
|
|
2021
Q2 | $547K | Sell |
2,713
-162
| -6% | -$33.9K | ﹤0.01% | 309 |
|
|
2021
Q1 | $618K | Sell |
2,875
-586
| -17% | -$129K | ﹤0.01% | 277 |
|
|
2020
Q4 | $818K | Buy |
3,461
+3,117
| +906% | +$715K | 0.01% | 238 |
|
|
2020
Q3 | $94K | Hold |
344
| – | – | ﹤0.01% | 499 |
|
|
2020
Q2 | $100K | Sell |
344
-139
| -29% | -$37.7K | ﹤0.01% | 485 |
|
|
2020
Q1 | $115K | Sell |
483
-870
| -64% | -$200K | ﹤0.01% | 422 |
|
|
2019
Q4 | $296K | Buy |
1,353
+798
| +144% | +$162K | ﹤0.01% | 385 |
|
|
2019
Q3 | $94K | Buy |
555
+51
| +10% | +$9.02K | ﹤0.01% | 551 |
|
|
2019
Q2 | $92K | Buy |
504
+93
| +23% | +$16.3K | ﹤0.01% | 497 |
|
|
2019
Q1 | $76K | Sell |
411
-116
| -22% | -$21.4K | ﹤0.01% | 526 |
|
|
2018
Q4 | $87K | Buy |
527
+155
| +42% | +$26.9K | ﹤0.01% | 460 |
|
|
2018
Q3 | $72K | Buy |
372
+2
| +0.5% | +$356 | ﹤0.01% | 490 |
|
|
2018
Q2 | $63K | Buy |
370
+214
| +137% | +$33.2K | ﹤0.01% | 474 |
|
|
2018
Q1 | $25K | Sell |
156
-29
| -16% | -$4.74K | ﹤0.01% | 557 |
|
|
2017
Q4 | $28K | Buy |
185
+9
| +5% | +$1.33K | ﹤0.01% | 592 |
|
|
2017
Q3 | $27K | Hold |
176
| – | – | ﹤0.01% | 548 |
|
|
2017
Q2 | $23K | Buy |
176
+156
| +780% | +$18.8K | ﹤0.01% | 578 |
|
|
2017
Q1 | $2K | Buy |
+20
| New | +$1.76K | ﹤0.01% | 767 |
|
|
2016
Q2 | – | Sell |
-115
| Closed | -$9K | – | 896 |
|
|
2016
Q1 | $9K | Buy |
+115
| New | +$10.4K | ﹤0.01% | 574 |
|
|
2015
Q4 | – | Sell |
-25
| Closed | -$3K | – | 806 |
|
|
2015
Q3 | $3K | Buy |
+25
| New | +$3.21K | ﹤0.01% | 770 |
|
|
2014
Q2 | – | Sell |
-48
| Closed | -$3K | – | 820 |
|
|
2014
Q1 | $3K | Buy |
+48
| New | +$3.8K | ﹤0.01% | 740 |
|
|
2013
Q3 | – | Sell |
-1,670
| Closed | -$134K | – | 796 |
|
|
2013
Q2 | $134K | Buy |
+1,670
| New | +$123K | ﹤0.01% | 427 |
|
Other funds holding VRTX
Brown Brothers Harriman & Co's VRTX Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, buying an estimated $1.31M and bringing the position to 8,785 shares worth $4.36M. The position accounts for 0.02% of the portfolio, ranked #239.
Brown Brothers Harriman & Co first reported a position in VRTX in Q2 2013 and has held it in 42 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Brown Brothers Harriman & Co held 8,785 shares of Vertex Pharmaceuticals worth $4.36M as of Q2 2026.
- Brown Brothers Harriman & Co bought 2,947 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
- Vertex Pharmaceuticals made up 0.02% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #239 holding.
- Brown Brothers Harriman & Co first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.